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Thyroid cancer
Maria E Cabanillas, David G McFadden, Cosimo Durante
Thyroid cancer is the fi fth most common cancer in women in the USA, and an estimated over 62 000 new cases 
occurred in men and women in 2015. The incidence continues to rise worldwide. Diff erentiated thyroid cancer is the 
most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either 
radioactive iodine or observation) is eff ective. Patients with other, more rare subtypes of thyroid cancer—medullary 
and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments 
that are approved for diff erentiated and medullary thyroid cancers have prolonged progression-free survival, but these 
drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.
Introduction
The incidence of thyroid cancer continues to rise 
worldwide, mostly as a result of increased use of 
diagnostic imaging and surveillance. Thyroid cancer is 
the fi fth most common cancer in women in the USA, 
and an estimated over 62 000 new cases occurred in men 
and women in 2015.1 Therefore, most practitioners will 
encounter a patient with this disease at some point in 
their career. Although incidence is rising steadily, 
mortality from thyroid cancer has changed minimally 
over the past fi ve decades. The challenge faced by 
physicians who treat thyroid cancers is to balance the 
therapeutic approach so that patients with lower risk 
disease or benign thyroid nodules are not over treated. At 
the same time, they need to recognise those patients with 
more advanced or high-risk disease, who need a more 
aggressive treatment approach. Thyroid cancers exhibit a 
broad range of clinical behaviour—from indolent 
tumours with low mortality in most cases, to very 
aggressive malignancies, for example, anaplastic thyroid 
cancer. Therefore, undertaking a proper diagnostic work-
up before treatment is started is crucial to appropriately 
tailor treatment. In this Seminar, we describe the clinical 
presentation, diagnostic work-up, and standard treatment 
of thyroid nodules and thyroid cancer, and discuss 
cutting-edge treatments that could be incorporated into 
standard care in the future.
Clinical presentation
Thyroid nodules
Thyroid nodules are being identifi ed with increasing 
frequency in clinical practice, owing largely to the growing 
use of diagnostic imaging. In studies using new high-
resolution imaging techniques, thyroid nodules are being 
identifi ed that would never have been diagnosed in the 
past.2–4 Although over 90% are small, non-palpable, benign 
lesions that will never become clinically signifi cant 
tumours,5,6 some patients have non-palpable or palpable 
lesions that are malignant. Identifi cation of malignant 
thyroid nodules is important, especially those that will cause 
morbidity if not diagnosed early. To distinguish between 
low-risk and high-risk patient subsets, a thorough history 
and physical examination, laboratory investigations, neck 
ultrasonography, and, for appropriately selected patients, 
fi ne-needle aspiration (FNA), are needed.7 Autonomous 
functioning thyroid nodules that cause hyperthyroidism 
should be identifi ed before biopsy to avoid complications 
and ensure appropriate imaging and treatment. A radio-
nuclide thyroid scan should be done only in patients with 
suppressed thyroid stimulating hormone (TSH).
Follicular-derived thyroid cancers
Diff erentiated thyroid cancer
Diff erentiated thyroid cancer is the most common 
thyroid cancer, accounting for more than 95% of cases,8 
and originates from thyroid follicular epithelial cells. 
Under the category of well-diff erentiated thyroid cancers 
are papillary thyroid cancer, follicular thyroid cancer, and 
Hurthle cell thyroid cancer. Poorly diff erentiated thyroid 
cancer is a more aggressive follicular-derived thyroid 
cancer than diff erentiated thyroid cancer.
Papillary thyroid cancer is the most common subtype 
and carries the best overall prognosis. Metastases most 
commonly involve cervical lymph nodes and, less 
commonly, the lungs. Follicular thyroid cancer, Hurthle 
cell thyroid cancer, and poorly diff erentiated thyroid 
cancers are high-risk cancers that have a tendency to 
metastasise haematogenously to distant sites, in particular, 
to lung and bones. The staging system for diff erentiated 
thyroid cancers depends on age,9 with older (≥45 years 
according to the current system) patients faring worse.
Anaplastic thyroid cancer
Anaplastic thyroid cancer is a rare form of thyroid cancer 
(<1%)8 that usually presents as a rapidly growing neck 
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Search strategy and selection criteria
We referred to key publications (including abstracts) and 
guidelines for the management of thyroid nodules and 
thyroid cancer. We also searched PubMed (Jan, 2005, to 
Dec 1, 2015) for the terms “thyroid nodule” and 
“diff erentiated thyroid cancer”, “medullary thyroid cancer”, or 
“anaplastic thyroid cancer” and cross-referenced these with 
the following terms: “genetics”, “management”, and “clinical 
trials”. We also cross-referenced “papillary thyroid cancer” 
with “surgery” and “lobectomy”. We restricted the search to 
studies done in human beings and published in English. 
We focused on publications after 2010. 
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mass. Patients often develop hoarseness, dysphagia, and 
dyspnoea. On examination, most patients with anaplastic 
thyroid cancer have a large, fi rm palpable mass in the 
thyroid with or without cervical adenopathy. This fi nding 
should prompt a rapid assessment and biopsy of the 
mass. A metastatic work-up often reveals locoregional 
disease and distant metastases. The most common site 
of distant metastatic disease is the lungs, followed by 
bones and brain. Anaplastic thyroid cancer often arises 
from and can coexist with diff erentiated thyroid cancer, 
but can also occur de novo. Clinicians should suspect 
anaplastic transformation in patients with a history of 
longstanding diff erentiated thyroid cancer if they present 
with the aforementioned symptoms. Referral to a centre 
with expertise in treating anaplastic thyroid cancer is 
recommended since these are rare tumours that have 
poor prognosis because of rapid tumour growth. 
Promising treatments are being tested in clinical trials 
(see later) and these might off er the best chance 
of survival.
Neuroendocrine C-cell derived thyroid cancer
Medullary thyroid cancer
Medullary thyroid cancer is uncommon, accounting 
for 1–2% of all thyroid cancers.8 By contrast with 
diff erentiated thyroid cancer, medullary thyroid cancer 
originates in the parafollicular neuroendocrine cells of 
the thyroid. It most commonly presents as a solitary 
thyroid nodule in patients in the fourth to sixth decade of 
life.10 Occasionally, neck lymphadenopathy is the fi rst 
manifestation, because the disease frequently meta-
stasises to cervical lymph nodes. 70% of patients 
presenting with a palpable medullary thyroid cancer have 
evidence of cervical node metastases at surgery.11 Some 
patients present with the classic case of a thyroid nodule, 
fl ushing and diarrhoea, which is suggestive of widespread 
metastatic disease. A quarter of medullary thyroid cancer 
cases occur in patients with an inherited multiple 
endocrine neoplasia syndrome.10
Genetics of thyroid cancer
Findings from DNA sequencing studies of thyroid cancer 
have revealed the genetic basis for most thyroid cancers. 
Most thyroid cancers harbour mutations along the 
mitogen-activated protein kinase (MAPK) cellular 
signalling pathway (fi gure 1). This pathway transmits 
growth signals from the plasma membrane to the 
nucleus and plays a central part in the regulation of 
cellular proliferation.12
Diff erentiated thyroid cancer and anaplastic thyroid cancer
The most frequent mutation in non-medullary thyroid 
cancer is the BRAFT1799A mutation, resulting in BRAFV600E-
mutant kinase, which is exclusive to papillary thyroid 
cancer13 and papillary-thyroid-cancer-derived anaplastic 
thyroid cancer. Mutations in the RAS family of 
oncogenes also occur frequently in thyroid cancer.14 RAS 
mutations most frequently occur in follicular thyroid 
cancer and follicular variant papillary thyroid cancer. 
Chromosomal translocations also occur in thyroid 
cancers. These genomic rearrangements lead to 
expression of novel fusion oncogenes that initiate events 
in many thyroid cancers. PAX8–peroxisome proliferator-
activated receptor γ (PPARγ) translocation occurs in 
about 30% of follicular thyroid cancer cases,15 and the 
RET-papillary thyroid cancer family of translocations 
targeting the RET oncogene occur in about 7% of 
papillary thyroid cancer cases.13 Less common 
translocation partner genes include BRAF, the NTRK 
gene family, ALK, and THADA.13 Although infrequent, 
these translocation events can directly aff ect treatment. 
For example, ALK rearrangements might be associated 
with clinically aggressive thyroid cancers.16 The 
availability of small-molecule ALK and NTRK gene 
family inhibitors have shown clinical promise in 
rearrangement-positive tumours in other cancers;17,18 
therefore, identifi cation of these rearrangements might 
have direct therapeutic relevance to patients with thyroid 
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Figure 1: Thyroid cancer pathways
Diagram shows the key molecular signalling pathways involved in thyroid 
cancer. The left box shows the mitogen-activated protein kinase pathway, which 
is activated by mutation in most thyroid cancers. These events are believed to 
initiate thyroid cancer development, and lead to altered gene expression, which 
promotes cell proliferation, cell growth, angiogenesis, and loss of 
diff erentiation. The right box shows pathways altered in advanced thyroid 
cancers, which are believed to promote tumour progression. This includes the 
PI3K–mTOR pathway, the p53 tumour suppressor, and alterations in the 
promoter for TERT. Blue boxes represents factors for which targeted treatments 
are available that have been approved by the US Food and Drug Administration. 
mTOR=mammalian target of rapamycin. PI3K=phosphatidylinositol-3-kinase. 
TERT=telomerase reverse transcriptase.
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cancer. Debate exists regarding the clinical implications 
of individual mutations, with fi ndings from some 
studies suggesting increased propensity for clinically 
aggressive papillary thyroid cancer in tumours bearing a 
BRAF mutation.19–23 However, the fact that about 50–70% 
of papillary thyroid cancers harbour a BRAF mutation13,24 
and most of these tumours remain indolent, suggests 
that other important determinants of clinical behaviour 
exist. Also, mutations in TERT have been identifi ed in 
more aggressive subsets of papillary thyroid cancer.25–27
Findings from DNA sequencing studies of poorly 
diff erentiated thyroid cancer and anaplastic thyroid 
cancer suggest that the acquisition of additional 
cooperating mutations contributes to tumour pro-
gression. Most commonly, a mutation that aff ects either 
the phosphatidylinositol-3-kinase or p53 tumour 
suppressor pathway is present, often in association with 
an early initiating mutation such as BRAFT1799A.14,28–30
Medullary thyroid cancer
Mutations in the RET proto-oncogene are believed to be 
the cause of most cases of medullary thyroid cancer, 
whereas a small proportion are caused by sporadic RAS 
mutations. RET mutations can occur sporadically as 
somatic events or as inherited germline events that 
exhibit autosomal dominant inheritance.10,31–33 Germline 
mutations in RET can predispose patients to early 
development of medullary thyroid cancer as a component 
of the multiple endocrine neoplasia type 2A and 2B 
syndromes. As such, patients who present at a young 
age are likely to have hereditary disease. Strong 
genotype–phenotype associations exist with specifi c RET 
mutations, which predict both the age of onset and the 
clinical aggressiveness of medullary thyroid cancer. 
Prophylactic thyroidectomy is often indicated, but 
specifi c recommendations are based on the age of the 
patient and the inherited mutation, and have been 
reviewed elsewhere.10
Because 1–7% of patients presenting with apparently 
sporadic medullary thyroid cancer are carriers of 
germline RET mutations,10 assessment for a heritable 
RET germline mutation should be recommended to all 
patients presenting with medullary thyroid cancer, 
regardless of their family history or age.
Assessment and treatment of thyroid nodules
Sonographic features that require FNA biopsy
Size plays a key part in identifying whether a FNA biopsy 
is needed for a thyroid nodule, but other sonographic 
fi ndings can also provide valuable clues regarding the 
likelihood of nodule malignancy. These include hypo-
echogenicity, a solid internal structure, irregular margins, 
microcalcifi cations, taller-than-wide shape, and evidence 
of extrathyroidal extension or cervical lymphadenopathy, 
or both.34 If a nodule has none of these features, FNA 
cytology can be deferred as long as the nodule remains 
small.19 These considerations apply mainly to papillary 
thyroid cancer. Follicular thyroid cancers, and follicular 
variant papillary thyroid cancers,35 are more often round 
and isoechoic with regular margins. In these cases, a 
larger size and increased intranodular vascularity on 
colour or power doppler imaging are also predictive of 
malignancy.36–39 The 2015 American Thyroid Association 
(ATA) guidelines19 include ultrasonography-defi ned risk 
categories for thyroid nodules, each with specifi c 
recommendations for FNA (fi gure 2).19 Consideration 
must also be given to concomitant clinical risk factors for 
thyroid cancer, which include the presence of a fi rm 
mass, neck pain, cough, voice change, and a history of 
childhood neck irradiation or familial thyroid cancer. In 
these cases, FNA can be considered regardless of the 
sonographic appearances.19 Beyond all these arguments, 
the 2015 ATA guidelines recommend biopsy only for 
nodules larger than 1 cm (fi gure 2).
Use of FNA cytology to tailor treatment
As shown in fi gure 2, the Bethesda system for reporting 
thyroid cytopathology includes six diagnostic categories.40 
Diagnostic category 2 includes benign nodules, which 
can be safely managed with periodic ultrasonography of 
the neck; nodules that are malignant (diagnostic 
category 6) or likely to be malignant (diagnostic category 5) 
generally need surgery.19 If cytology results are non-
diagnostic (diagnostic category 1), the nodule should 
be re-aspirated. Indeterminate results (diagnostic 
categories 3 and 4, the latter suggesting a higher 
probability of malignancy) can be managed surgically or 
with close monitoring, depending on clinical risk factors, 
ultrasonography patterns, and patient preferences.19
Molecular diagnostics for diff erentiating between 
diagnostic categories 3 and 4
A cytological diagnosis of malignancy has a high 
specifi city and positive predictive value, and conversely a 
cytological diagnosis of a benign nodule has a high 
negative predictive value and low false negative rate. 
However, thyroid nodule FNA cytology is confounded in 
diagnostic categories 3 and 4, in which the diagnosis or 
exclusion of thyroid cancer is not clear.19 Two approaches 
to molecular diagnosis of indeterminate thyroid nodules 
are in use: gene mutation profi ling panels and a 167 gene 
expression classifi er.41–43 A positive test for a mutation in 
genotyping panels has a high predictive value for thyroid 
cancer. By contrast, the 167 gene expression classifi er 
off ers a strong negative predictive value, but a suspicious 
result is predictive of thyroid cancer in only 50% of cases. 
Therefore, mutation testing is regarded as a good rule-in 
test, by contrast with the gene expression classifi er, which 
is regarded as a good rule-out test. However, a more 
recent, expanded mutation panel seems to improve the 
poor negative predictive value of early seven-gene 
mutation tests.43,44 Findings from an initial study45 showed 
that use of the 167 gene expression classifi er reduced the 
number of surgeries for benign thyroid nodules, but 
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fi ndings from recent reports suggested large inter-
institutional variation in the usefulness and cost-
eff ectiveness of this test.19,46–48 Although expanded 
mutation profi ling panels seem to overcome some 
weaknesses of the gene expression classifi er assay, 
additional studies validating the mutation panel at several 
institutions is necessary. Therefore, the use of these tests 
to improve patient care remains to be established. 
However, the era of molecular diagnosis in thyroid 
nodules is underway, and molecular approaches are likely 
to continue to improve the diagnostics of thyroid nodules.
Treatment of diff erentiated thyroid cancer
The pretreatment assessment of risk for patients with 
diff erentiated thyroid cancer includes neck imaging 
techniques. Cervical ultrasonography plays a key part, by 
providing surgeons with fundamental information on 
the size, location, number of tumours and lymph nodes, 
and local invasion of surrounding tissues. In up to a 
third of patients with diff erentiated thyroid cancer, nodal 
lesions are identifi ed on the preoperative scan, and in 
two-thirds of these cases the fi ndings lead to revision of 
the surgical plan.49,50
Surgical approaches 
Primary treatment decisions are based on a preoperative 
risk assessment that includes clinical, imaging, and 
cytological data. Choices depend on the location or 
locations and extent of identifi able disease (ie, therapeutic 
surgery) and the risk that unidentifi able disease foci are 
also present (ie, prophylactic surgery; fi gure 3). With 
increasing emphasis on risk-stratifi ed management, the 
treatment approaches recommended by the 2015 ATA 
guidelines19 are more conservative than in the past. 
Lobectomy is an option for unifocal tumours smaller 
than 4 cm with no evidence of extrathyroidal extension or 
lymph node metastasis. The results of several large 
database studies51–54 have shown that unilateral and 
bilateral resections are associated with similar long-term 
survival. In these cases, overall survival is also unaff ected 
by the presence of occult lymph node metastases.55 With 
one lobe intact, many patients can avoid lifelong thyroid 
hormone replacement therapy. Complication rates 
associated with lobectomy are roughly half those reported 
with total thyroidectomy.56 In the presence of small, non-
invasive, clinical N0 tumours, risk:benefi t ratios might 
favour a plan that includes lobectomy with intraoperative 
Neck ultrasonography sonographic pattern19
Benign or very low suspicion
<3% risk of malignancy19
• Purely cystic nodules
• Spongiform or partially 
cystic nodules
Low suspicion
5–10% risk of malignancy19
• Partially cystic nodules with 
eccentric solid areas
• Solid isoechoic or hyperechoic 
nodules 
Intermediate suspicion 
10–20% risk of malignancy19
• Solid hypoechoic nodules with 
smooth margins
High suspicion
>70–90% risk of malignancy19
• Solid hypoechoic nodules or solid 
hypoechoic component of a 
partially cystic nodule with one 
or more of the following: irregular 
margins, microcalcifications, 
taller-than-wide shape, rim 
calcifications with small extrusive 
soft-tissue component, 
extrathyroid extension, and 
suspicious lymph nodes
FNAC DCs in order of increasing risk of malignancy40
Benign (DC 2)
<3% risk of 
malignancy
Non-
diagnostic 
(DC 1)
1–4% risk of 
malignancy
AUS or FLUS 
(DC 3)
5–15% risk of 
malignancy
FN or SFN 
(DC 4)
15–30% risk 
of malignancy
Suspicious 
(DC 5)
60–75% risk 
of malignancy
Malignant 
(DC 6)
97–99% risk 
of malignancy
Surveillance* Repeat FNAC Surveillance or surgery† Surgery
>1 cm>1 cm>1·5 cm
Figure 2: Management of thyroid nodules on the basis of sonographic patterns and cytology diagnostic categories of the Bethesda system
AUS=atypia of undetermined signifi cance. DC=diagnostic category. FLUS=follicular lesion of undetermined signifi cance. FN=follicular neoplasm. FNAC=fi ne-needle 
aspiration cytology. SFN=suspicious for follicular neoplasm. *Fine-needle aspiration can be considered (1) for nodules with very low suspicion sonographic pattern 
and the largest diameter greater than 2 cm; and (2) if there are suspicious clinical fi ndings (eg, fi rm mass, neck pain, cough, voice change, and a history of childhood 
neck irradiation or familial thyroid cancer), regardless of the sonographic appearances. †Indeterminate results can be managed surgically or with close monitoring, 
depending on the clinical risk factors, ultrasonography patterns, genetic testing, and patient preferences. 
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inspection of the central compartment, and upgrade to 
total thyroid ectomy with compartmental neck dissection 
should nodal disease be found.19 The rare recurrences 
that develop during long-term follow-up of patients 
treated with lobectomy can be detected readily and 
controlled appropriately with completion surgery without 
jeopardising survival.57,58 However, this evidence is based 
on fi ndings from case-control and registry database 
studies, which might give rise to bias, and randomised 
controlled trials examining the safety and effi  cacy of 
lobectomy are needed. For carefully selected patients 
presenting with papillary microcarcinomas (≤1 cm) 
without evidence of cervical lymph node metastases, 
non-surgical management can be an option. Researchers 
in Japan have found strong evidence of the safety and 
effi  cacy of active surveillance in these cases.59,60 Surgery 
was done in patients with substantial increases in nodule 
size. The medical–economic implications of this 
approach are unknown.
Management after primary surgery
Shortly after surgery, the risk estimate is adjusted based 
on surgical and pathological fi ndings, and decisions are 
made regarding the need for radioiodine ablation or 
TSH suppression, or both. This assessment is 
conventionally based on the well-known TNM staging 
system. TNM staging was designed to predict 
mortality61,62 and is less eff ective for estimating the 
probability of postoperative persistence or recurrence of 
disease, which is more pertinent to follow-up planning. 
The need for estimation of risk of recurrence was 
addressed by the ATA in 2009, with a new system that 
identifi es high, intermediate, and low risk for 
recurrence.63 This system is a reliable predictor of the 
Surgery: procedure of choice for differentiated thyroid cancer19
Lobectomy*
Preoperative findings:
• Unifocal thyroid cancer ≤1 cm
and
• No evidence of 
• extrathyroid extension 
(clinical T3/T4)  
• neck lymph node metastases 
(clinical N0)
• distant metastases 
(clinical M0)
Lobectomy or total 
thyroidectomy
Preoperative findings:
• Thyroid cancer >1 cm and <4 cm
and
• No evidence of 
• extrathyroid extension 
(clinical T3/T4)  
• neck lymph node metastases 
(clinical N0)
• distant metastases 
(clinical M0)
Total thyroidectomy
Preoperative findings:
• Thyroid cancer ≥4 cm 
and
• No evidence of 
• gross extrathyroid extension 
(clinical T4) 
• neck lymph node metastases 
(clinical N0)
• distant metastases 
(clinical M0)
Total thyroidectomy with lymph 
node dissection 
Preoperative findings:
• Evidence of lymph node 
metastases (clinical N1; 
therapeutic lymph node 
dissection)
or
• Papillary thyroid cancer with 
evidence of 
• gross extrathyroid extension 
(clinical T4)  
• distant metastases 
(clinical M1; prophylactic
   central neck dissection)
Indications for radioactive iodine as adjuvant treatment19
No
Postoperative findings:
• Tumour size ≤1 cm (T1a)
• Unifocal or multifocal
Not routine
Postoperative findings:
• Tumour size >1 cm to 
<4 cm (T1b–T2)
• Follicular thyroid cancer 
with no or minimal 
(<4 foci) vascular 
invasion
Consider
Postoperative findings:
• Tumour size ≥4 cm (T3)
• Microscopic extrathyroid 
extension (T3)
• Central compartment 
neck lymph node 
metastases (N1a)†
• Lateral neck lymph 
node metastases (N1b)
Yes
Postoperative findings:
• Follicular thyroid cancer 
with extensive (>4 foci) 
vascular invasion
• Gross extrathyroid 
extension (T4)
• Distant metastases (M1) 
Figure 3: Primary treatment of patients with diff erentiated thyroid carcinoma
*For patients with known clinical risk factors (eg, previous head and neck irradiation or familial thyroid carcinoma), the initial surgical procedure should be total 
thyroidectomy. Lobectomy can be off ered to patients with small, intrathyroidal tumours with no clinical evidence of metastasis. After lobectomy, completion 
thyroidectomy could be off ered to patients with evidence of pathological extrathyroid extension or lymph node involvement, or both. †There is insuffi  cient evidence 
to recommend radioactive iodine in patients with fewer than fi ve microscopic nodal metastases in the central compartment, without extra-nodal extension. 
For indications for radioactive iodine, solid lines show pateints for whom we strongly recommended consideration of radioactive iodine based on preoperative 
fi nding and the dsashed line shows patients who can be considered for radioactive iodine depending on the pathological postoperative fi ndings.
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course of diff erentiated thyroid cancer treated with 
thyroidectomy alone64,65 or with radioactive iodine 
remnant ablation.64,66–68 The revised system proposed in 
the ATA’s 2015 guidelines19 includes additional clinical 
and pathological features, allowing more precise 
estimates of the risk of recurrence (panel).
Primary management with radioactive iodine
The decision to administer radioactive iodine treatment 
after total thyroidectomy is often justifi ed by the need to 
eliminate residual clusters of normal thyroid tissue. The 
ability of this tissue to incorporate iodine and produce 
thyroglobulin complicates eff orts to identify persistent or 
recurrent neoplastic thyroid tissue with ¹³¹I scintigraphy 
and serum thyroglobulin assays. This rationale is now 
being challenged. In the past two decades, use of 
diagnostic whole-body ¹³¹I scintigraphy has reduced 
sharply, and reliance on cervical ultrasonography,69,70 
which is not only more sensitive, but also advantageous in 
terms of cost, radiation exposure, and absence of adverse 
eff ects,71 has increased. Neck ultrasonography combined 
with serum thyroglobulin assays are the most sensitive 
methods for detecting persistent disease and tailoring 
subsequent diagnostic and therapeutic strategies.19,69,70
Radioiodine is also advocated as adjuvant treatment, 
with the aim of improving long-term outcomes by 
destroying occult microscopic foci of neoplastic cells 
within the thyroid remnant or elsewhere in the body. This 
practice has also been questioned in the past decade.63 The 
adverse eff ects of radioiodine include short-term morbidity 
and possible increases in the risk of second cancers.72,73 
Guidelines now recommend selective use of radioactive 
iodine, based on individual risk, with the lowest activity 
needed to ensure successful treatment (fi gure 3).19
Lastly, radioactive iodine can be used to identify patients 
with distant metastatic disease that is sensitive to 
radioactive iodine, and also serves as a treatment. 
Unfortunately, many patients are refractory to radioactive 
iodine; in these patients this strategy would not be eff ective 
for either detection or treatment of distant disease.
TSH suppression treatment
Circulating TSH stimulates proliferation in normal 
thyrocytes and most thyroid cancer cells.74 For this reason, 
TSH-suppressive doses of thyroid hormone therapy have 
traditionally been used after surgery. This approach 
signifi cantly reduces recurrence and cancer-related 
mortality in patients with diff erentiated thyroid cancer.75 
However, the amount of suppression needed to attain these 
goals is unclear. In high-risk patients, reducing TSH 
concentrations to less than 0·1 mU/L can improve clinical 
outcomes,76 but moderate reductions (subnormal to normal 
TSH) can also improve outcomes.77 However, the subclinical 
hyperthyroidism induced by TSH can negatively aff ect the 
bone (causing osteoporosis in postmenopausal women) 
and heart (causing angina in patients with coronary heart 
disease and atrial fi brillation in elderly patients).78 The 
likelihood of complications must be weighed against the 
risk of increasing tumour cell proliferation, on the basis of 
ongoing assessments of the individual’s risk of persistent 
or recurrent disease (appendix).19
Panel: Recurrence risk stratifi cation at the time of primary treatment and over time 
as a function of the response to treatment
At the time of primary treatment
ATA low risk (≤5% recurrence)
Papillary thyroid cancer
• Intrathyroid tumour
• Clinical N0 or fi ve or fewer lymph node micrometastases (<0·2 cm in largest diameter)
• V600EBRAF-mutated microcarcinoma
Follicular thyroid cancer
• Intrathyroid tumour
• Capsular invasion and no or minimal (<4 foci) vascular invasion
ATA intermediate risk (5–20% recurrence) 
Papillary thyroid cancer
• Minimal extrathyroid extension
• Aggressive histology*
• Vascular invasion
• Clinical N1 or more than fi ve lymph node metastases (<3 cm in largest diameter)
• V600EBRAF-mutated, intrathyroid, 1–4 cm, primary tumour
• V600EBRAF-mutated microcarcinoma, multifocal with extrathyroid extension
ATA high risk (>20% recurrence)
Papillary thyroid cancer
• Gross extrathyroid extension
• Distant metastases
• Lymph node metastasis at least 3 cm in largest diameter
Follicular thyroid cancer
• >4 foci of vascular invasion
During follow-up†
Excellent response (1–4% recurrence)
• Imaging negative for disease recurrence
• Serum thyroglobulin concentration lower than 0·2 ng/mL basal or higher than 
1 ng/mL TSH stimulated‡
Indeterminate response (15–20% recurrence)
• Non-specifi c fi ndings on imaging studies
• Serum thyroglobulin 0·2–1 ng/mL basal or 1–10 ng/mL TSH stimulated, or 
thyroglobulin antibodies stable or decreasing
Biochemical incomplete response (20% recurrence) 
• Imaging negative for disease recurrence 
• Serum thyroglobulin concentration higher than 1 ng/mL basal or higher than 
10 ng/mL TSH stimulated, or increasing thyroglobulin antibody concentrations
Structural incomplete response (50–85% recurrence)§
• Structural (neck ultrasound, CT, or MRI) or functional (whole-body scan or 
18F-fl uorodeoxyglucose PET) evidence of disease in imaging studies
ATA=American Thyroid Association. TSH=thyroid stimulating hormone. *Tall cell, hobnail variant, and columnar cell carcinoma. 
†The initial risk stratifi cation should be updated continually and revised after the primary treatment on the basis of data gener-
ated during periodic follow-up visits. This approach is valid soon after surgery (1–3 months) to decide whether or not radio-
active iodine should be given for adjuvant or therapeutic purposes. ‡In the absence of interfering thyroglobulin antibodies. 
§Percentage of patients who will continue to have persistent disease despite additional treatment. Adapted with permission 
from Haugen and colleagues.19 
See Online for appendix
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Assessment of individual risk during follow-up
6–12 months after postoperative assessment, the patient’s 
risk status should be revised based on their response to 
primary treatment, which is classifi ed according to the 
system shown in the panel.19,64,66 This checkpoint is 
mandatory and involves measurement of thyroglobulin 
concentrations, neck ultrasonography, and other 
examinations as needed. The results are essential for 
planning the next few years of follow-up, which are 
important, since 77% of recurrences are discovered 
during the fi rst 5 years after surgery.79 Even so, the risk 
estimate is updated continually and revised based on 
data generated during follow-up visits. With this dynamic 
approach, a substantial proportion of patients with 
diff erentiated thyroid cancer—including some whose 
initial staging revealed a high risk of persistent or 
recurrent disease—can at some point be reclassifi ed as 
having a lower risk of recurrence and shifted onto a 
surveillance programme that is less intensive than 
originally planned. Recurrences detected during the 
surveillance period are usually managed with either 
observation (for small clinically insignifi cant lesions) or 
comprehensive compartmental surgery.
Treatment of medullary thyroid cancer
Surgery is the only curative treatment for medullary 
thyroid cancer; however, few patients with clinically 
apparent nodal metastases at diagnosis achieve 
undetectable tumour markers. As with diff erentiated 
thyroid cancer, imaging and diagnosis before surgery are 
crucial to deliver the appropriate surgical intervention. All 
patients with a preoperative diagnosis of medullary 
thyroid cancer should undergo comprehensive neck 
ultrasonography and tumour marker (calcitonin and 
carcinoembryonic antigen) measurement. Additionally, 
establishing whether the patient has germline or sporadic 
disease is crucial because patients with multiple endocrine 
neoplasia type 2 can have pheochromocytoma or primary 
hyperparathyroidism, or both. If germline RET mutation 
status is not known or cannot be established before surgery 
in a patient with medullary thyroid cancer, biochemical 
testing should be done to rule out pheochromocytoma and 
hyperparathyroidism. If the patient has primary hyper-
parathyroidism, thyroid surgery should be tailored to 
include parathyroidectomy. Adrenalectomy in patients 
with pheochromocytoma should be prioritised before 
thyroidectomy. Referral to a genetic counsellor for patients 
with hereditary medullary thyroid cancer is recommended 
so that only appropriate family members undergo testing, 
which reduces the cost. The use of prophylactic 
thyroidectomy for family members who carry the germline 
RET mutation has been reviewed elsewhere.10
Tumour markers in the preoperative setting
If the preoperative calcitonin concentration is higher than 
146 pmol/L, further work-up for distant metastatic disease 
should be done.10 The recommended imaging for this 
work-up includes neck and chest CT and three-phase 
contrast-enhanced MRI of the liver. Skeletal metastases 
are preferably assessed with axial skeleton MRI. In the 
absence of substantial distant metastatic disease, the 
preferred surgery is total thyroidectomy with bilateral 
central neck dissection. Dissection of lateral neck 
compartments is recommended only if metastatic disease 
is suspected by neck ultrasound and confi rmed by FNA 
cytology. The revised ATA guidelines10 for the management 
of medullary thyroid cancer recommend contralateral 
neck dissection in patients with lateral neck disease based 
on calcitonin concentrations higher than 58 pmol/L; 
however, this recommendation remains controversial. 
Management after primary surgery
The long-term management of medullary thyroid cancer 
primarily consists of observation. Patients need thyroid 
hormone replacement but not suppression of TSH, as is 
done in high-risk diff erentiated thyroid cancer. Tumour 
markers (calcitonin and carcinoembryonic antigen) 
should be checked no earlier than 3 months after surgery 
to establish whether the patient has persistent disease. 
External beam radiation should be used sparingly because 
it can limit future surgical intervention because of the 
induction of fi brosis. External beam radiation can also 
reduce the quality of life of the patient. Referral to a 
centre with expertise in medullary thyroid cancer is 
recommended for patients for whom external beam 
radiation is not clearly indicated. Most patients should be 
managed with active surveillance, whereby both ultra-
sonography and tumour markers are assessed serially to 
guide further surgical treatment. Locally recurrent 
disease can be managed with observation or surgery, 
depending on the risk of the tumour threatening vital 
structures and other patient factors.
Use of tumour markers after primary surgery
Patients with undetectable tumour markers and normal 
imaging after surgery should continue to be followed up 
annually; those with persistent tumour markers need to 
be followed up more closely for progression. Calcitonin 
and carcinoembryonic antigen doubling times are useful 
measures, because they are predictive of outcomes and 
aggressive tumour behaviour.80 Patients with calcitonin 
and carcinoembryonic antigen doubling times within 
6 months have a shorter overall survival. An online 
calculator can be found on the ATA website.
Systemic treatments for advanced stage 
diff erentiated thyroid cancer and medullary 
thyroid cancer
Identifi cation of patients who should be considered for 
systemic treatment
Much progress has been made in the treatment of 
advanced thyroid cancer with the approval of four kinase 
inhibitors for diff erentiated thyroid cancer and medullary 
thyroid cancer. Unfortunately, these drugs are not curative 
For the ATA website see 
http://thyroid.org
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and patients eventually develop resistance. Furthermore, 
many patients with metastatic or recurrent diff erentiated 
thyroid cancer and medullary thyroid cancer have indolent 
disease. Thus, these drugs are reserved for patients with 
progressive disease or those with disease that is 
threatening vital structures or causing substantial clinical 
symptoms. Patients with diff erentiated thyroid cancer 
should have radioactive iodine-refractory disease (fi gure 4) 
before systemic treatments are considered. Figure 5 
shows the recommended treatment for a patient with 
diff erentiated thyroid cancer or medullary thyroid cancer 
who has locoregional or distant metastatic disease and the 
indications for starting systemic treatment. Observation 
for progressive disease is important because most patients 
with diff erentiated thyroid cancer and medullary thyroid 
cancer have indolent disease. Localised treatments can be 
considered for patients with progressive disease, thereby 
delaying the need for systemic treatment. For example, 
external beam radiation or embolisation for bony or liver 
metastases in patients in whom these are likely to cause 
morbidity.19 In patients with locoregional disease, surgery 
should be considered in the appropriate setting, and 
metastasectomy can be used for low-volume metastatic 
disease if it will delay or prevent morbidity. For example, a 
patient with a bony metastasis that is threatening function 
of the limb could be considered for surgery.19 
Systemic treatments for advanced stage diff erentiated 
thyroid cancer
In the past several years, considerable research dedicated 
to diff erentiated thyroid cancer has been done, leading to 
the approval of two kinase inhibitors for use in 
diff erentiated thyroid cancer by the US Food and Drug 
Administration and European Medicines Agency: 
sorafenib and lenvatinib. These drugs are multikinase 
inhibitors with antiangiogenic properties. Other classes 
of drugs have been studied in diff erentiated thyroid 
cancer and hold promise for the treatment of patients 
with advanced, widely metastatic disease.82–91
Sorafenib was approved for diff erentiated thyroid 
cancer in 2013 on the basis of favourable results of a 
phase 3 multicentre, randomised, double-blind, placebo-
controlled clinical trial (DECISION).92 The lenvatinib 
SELECT trial85 was also a phase 3 multicentre, 
randomised, double-blind, placebo-controlled clinical 
trial in patients with diff erentiated thyroid cancer. The 
impressive results of this trial led to the approval of the 
drug in the USA in 2015. The table shows the results and 
important diff erences in trial design between the trials 
that resulted in the approval of these drugs. Neither trial 
showed a statistically signifi cant diff erence in overall 
survival; however, both trials allowed for unmasking and 
crossover at progression. In a subgroup analysis of 
SELECT, a signifi cant improvement in overall survival 
was noted in older (>65 years) compared with younger 
(≤65 years) patients.96
These kinase inhibitors are also associated with adverse 
eff ects. Common adverse eff ects associated with sorafenib 
and lenvatinib are hypertension, hand–foot skin reaction, 
diarrhoea, rash, fatigue, weight loss, and stomatitis. 
Increased TSH concentration is also common and is 
particularly concerning for patients with diff erentiated 
thyroid cancer, who should have TSH suppressed.
Systemic treatments for advanced stage medullary 
thyroid cancer
Both vandetanib and cabozantinib are approved in the 
USA and EU for treatment of medullary thyroid cancer. In 
the phase 3, multicentre, double-blind, placebo-controlled 
trial of vandetanib (ZETA),94 adult patients with locally 
advanced or metastatic medullary thyroid cancer were 
enrolled. Unmasking and crossover was permitted in 
No RAI uptake in any lesion ≥1 lesion without RAI uptake Progression of RAI-avid lesions
No uptake Uptake
Figure 4: Defi nition of diff erentiated thyroid cancer refractory to radioactive iodine
The standard defi nition of patients who are refractory to RAI is those with metastatic lesions that have no RAI uptake, 
or one or more lesion that does not have any RAI uptake, or progression of lesions that do have RAI uptake. Most 
defi nitions also include patients who have received greater than 600 mCi cumulative dose of RAI because those 
patients do not seem to benefi t from additional treatment.81 RAI=radioactive iodine. 
Observation for progression 
Localised treatments when feasible
Consider systemic treatment
Indications for systemic treatment in 
patients with thyroid cancer, any one of:
• Clinically significant disease* and evidence 
of disease progression
• Symptomatic tumour burden that cannot 
be managed with localised treatments or 
other medical treatment
• Tumour threatens vital structures and 
cannot be managed with localised 
treatments
Consider surgery for locoregional or low-
volume distant metastatic disease
Locoregional or distant metastatic disease
Figure 5: Treatment approach for a patient with diff erentiated and medullary thyroid cancer with 
locoregional or distant metastatic disease and the indications for initiating systemic treatment
*A tumour that measures at least 1·5 cm. In diff erentiated thyroid cancer, patients should also have evidence of 
disease refractory to radioactive iodine.
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ZETA at the time of progression. Cabozantinib was 
studied in a phase 3, multicentre, randomised, double-
blind, placebo-controlled clinical trial (EXAM).95 Patients 
in EXAM were never unmasked and were not permitted 
to crossover to open-label drug. This diff erence in masking 
and crossover and the inclusion of patients only with 
progressive disease were the major design diff erences 
between EXAM and ZETA. The results of both trials are 
summarised in the table.
So far, neither trial has shown an overall survival 
advantage of the drug versus placebo. In the vandetanib 
trial,94 overall survival data were immature since only 
15% of patients had died at the progression-free survival 
cutoff . As for the cabozantinib trial,95 despite not 
permitting for crossover, overall survival was not 
statistically diff erent between the two arms. However, in 
2015, Schlumberger and colleagues97 reported a 
statistically signifi cant diff erence in overall survival 
between patients with RET M918 mutations who received 
cabozantinib compared with placebo (44·3 vs 18·9 months, 
hazard ratio 0·60, 95% CI 0·38–0·95).
Similar to sorafenib and lenvatinib, diarrhoea, rash, 
hypertension, fatigue, hand–foot skin reaction, and 
headaches are common adverse eff ects associated 
with vandetanib and cabozantinib.94,95 Gastrointestinal 
perforation and fi stula formation are rare but serious 
adverse eff ects associated with cabozantinib.98 QTc 
prolongation was reported in 8% of patients in the ZETA 
trial,94 leading to the requirement of a risk assessment 
and mitigation strategies programme for physicians to 
be allowed to prescribe the drug. 
Treatment of anaplastic thyroid cancer
Anaplastic thyroid cancer is an aggressive form of thyroid 
cancer, and is both a diagnostic and therapeutic challenge 
because of the rarity of the disease and because anaplastic 
thyroid cancer cells lose expression of thyroid and 
epithelial cell markers.99 Additionally, these tumours can 
exhibit diverse histomorphological abnormalities, such as 
squamoid, spindled patterns, leading to confusion about 
the organ of origin. This confusion can lead to a delay in 
diagnosis and initiation of an appropriate treatment plan. 
Once diagnosis is established, patients should be staged 
quickly (appendix), and the airway should be assessed by 
fi breoptic laryngoscopy. A treatment plan must be devised 
and implemented quickly.
Referral to a centre with experience with anaplastic 
thyroid cancer is recommended. Treatment of local disease 
in the neck is multimodal.100 Patients should be assessed by 
an experienced head-and-neck surgeon to establish 
whether the primary tumour is resectable. External beam 
radiation is recommended soon after resection, preferably 
with radiosensitising drugs such as some combinations of 
taxanes with or without platin or anthracyclines (chemo-
radiation). Patients with unresectable primary tumours, 
but without detectable distant metastases, are usually 
referred for palliative chemoradiation.
The most challenging cases are patients who present 
with advanced distant metastatic disease (stage IVC). The 
physician must balance the goal of local control of the 
primary tumour with treatment of distant metastases. If 
locoregional disease is an imminent threat then chemo-
radiation should be given fi rst. For those patients in 
whom the airway is not at risk or has already been 
stabilised by tracheostomy, systemic chemotherapy with 
cytotoxic drugs or, preferably, enrolment in a clinical trial 
should be considered.
A recent approach is targeted treatment of the cancer; 
for example, BRAF inhibitors in patients with 
BRAFV600E-mutated anaplastic thyroid cancer.101 A trial 
with the selective BRAF inhibitor dabrafenib and the 
MEK inhibitor trametinib is accruing patients 
(NCT02034110). Other interesting drugs being studied 
are lenvatinib (NCT02657369),102 second-generation 
mammalian target of rapamycin (mTOR) inhibitors 
(NCT02244463), microtubule inhibitors (NCT01240590), 
Trial design Trial results (drug vs placebo)
Drug targets Label indication in 
thyroid cancer
Notable entry criteria Randomisation 
and design 
(drug vs placebo)
PFS, months (HR, 95% CI; 
p value)
Complete 
response 
(%)
Partial 
response 
(%)
Stable disease 
(%)
Sorafenib92 VEGFR1, VEGFR2, 
VEGFR3, RET, BRAF, 
PDGFR
DTC refractory to 
radioactive iodine
Adult, DTC refractory to radioactive 
iodine, treatment naive, progression 
within 14 months 
1:1; crossover 
allowed
10·8 vs 5·8 (0·59, 0·45–0·76; 
p<0·0001)
0 vs 0 12·2 vs 0·5 41·8 vs 33·2*
Lenvatinib93 VEGFR1, VEGFR2, 
VEGFR3, RET, PDGFR, 
FGFR1, FGFR2, FGFR3, 
FGFR4
DTC refractory to 
radioactive iodine
Adult, DTC refractory to radioactive 
iodine, one previous VEGF-directed 
treatment allowed, progression 
within 13 months
2:1; crossover 
allowed
18·3 vs 3·6 (0·21, 99% CI 
0·14–0·31; p<0·001)
1·5 vs 0 63·2 vs 1·5 23 vs 54·2
Vandetanib94 VEGFR2, RET, EGFR MTC Adult, MTC 2:1; crossover 
allowed
30·5† vs 19·3 (0·46, 0·31–0·69; 
p<0·001)
0 vs 0 45 vs 13 NA
Cabozantinib95 VEGFR2, RET, MET MTC Adult, MTC, progression within 
14 months
2:1; crossover not 
allowed
11·2 vs 4·0 (0·28, 0·19–0·40; 
p<0·001)
0 vs 0 28 vs 0 48·1 vs 50
All trials were randomised, double-blind, placebo-controlled trials in which PFS was the primary endpoint. All trials met the primary endpoint. DTC=diff erentiated thyroid cancer. HR=hazard ratio. MTC=medullary 
thyroid cancer. NA=not assessed. PFS=progression-free survival. *For >6 months. †Estimated. 
Table: Phase 3 trial results of the four drugs approved for advanced thyroid cancer
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PPARγ agonists (NCT02152137), and immunotherapy 
(NCT02458638 and NCT02239900). Immunotherapy 
might be a diffi  cult approach since this class of drugs 
tends to induce regression of tumour months after 
starting treatment. In patients who need to respond to 
treatment quickly, drugs that take eff ect within weeks 
rather than months are needed.
As with many advanced, aggressive malignancies, 
patients and family members need to understand the 
poor prognosis, and advanced directives and wishes of 
the patient should be discussed. Some patients should be 
referred to a hospice if their performance status is poor 
or they do not wish to pursue treatment.
Summary and future directions
The management of early-stage and late-stage thyroid 
cancer, as well as approaches to thyroid nodules, has 
changed markedly in the past decade. Molecular analysis 
of indeterminate thyroid nodules is beginning to infl uence 
disease management; however, no test has so far been able 
to discriminate malignant from benign nodules reliably. 
Dynamic risk stratifi cation for patients with diff erentiated 
thyroid cancer and the recognition that many diff erentiated 
thyroid cancers warrant a more conservative approach 
should lead to fewer total thyroidectomies, reduce use of 
radioactive iodine, and relax TSH suppressive treatment in 
appropriately selected patients.
Prospective randomised clinical trials on management 
of primary diff erentiated thyroid cancer have not yet been 
done, in part because of the overall low mortality and long 
survival of most patients, which has led to a general 
paucity of interest by pharmaceutical companies and 
investigators alike. However, most diff erentiated thyroid 
cancer recurrences occur in the fi rst 3 years after initial 
treatment, and therefore these studies are feasible.103 One 
important future direction is execution of prospective 
clinical trials to address major management decisions 
including, but not limited to, the use of radioactive iodine 
for remnant ablation and adjuvant treatment for low-risk 
or intermediate-risk disease, and optimum initial surgical 
approaches. Additionally, as molecular markers and 
analyses are applied to clinical care, prospective studies 
should integrate these methods into trial designs.
That four antiangiogenic drugs have been approved for 
advanced thyroid cancer in just 4 years is remarkable. 
A better understanding of the optimum time to start 
treatment and which groups of patients warrant 
treatment will continue to evolve. Other novel treatments 
have been studied and hold promise in BRAF-mutated 
papillary thyroid cancer, including the selective BRAF 
inhibitors vemurafenib82,104 and dabrafenib.83 As more 
mutations are being recognised and becoming drug 
targets (eg, the NTRK gene family and ALK molecular 
abnormalities), more clinical trials are being planned.
One exciting area of active research involves 
modulation of the diff erentiation state (ie, how similar 
the cancer cell remains to the parental cell of origin) of 
diff erentiated thyroid cancer. Findings from the large 
TCGA study13 of papillary thyroid cancer showed that 
BRAFV600E-like and RAS-like classes of papillary thyroid 
cancer diff er signifi cantly with respect to diff erentiation 
state, with BRAFV600E-like tumours exhibiting a gene 
expression profi le associated with a less diff erentiated 
state. Findings from two proof-of-concept clinical 
trials86,87 in patients with thyroid cancers refractory to 
radioactive iodine have supported this hypothesis. In 
one trial,87 selumetinib, a selective MEK inhibitor, was 
used as a re-diff erentiating drug, and in the other,86 
dabrafenib, a selective BRAF inhibitor, was used in 
patients with BRAF-mutated papillary thyroid cancer. In 
both trials, patients with measurable disease were 
treated over a short timeframe then re-imaged for new 
or increased radioiodine uptake by the tumour. In each 
study, most patients exhibited new or increased 
radioiodine uptake. Future studies should focus on 
patients with earlier stage disease and those with smaller 
target lesions, because these patients have the highest 
chance of a cure with this approach.
New methods to treat patients with medullary thyroid 
cancer who fail to respond or progress on vandetanib or 
cabozantinib, or both, are needed. The role of cancer 
immunotherapies is being studied in medullary thyroid 
cancer,105 but no clinical trials are enrolling at the 
moment. The major limitation to discovering eff ective 
treatments for anaplastic thyroid cancer is the rarity of 
the disease. Patients and their advocates will need to lead 
the way to push for approval of treatments on the basis of 
fi ndings from small trials since completion of larger 
trials are not feasible.
The molecular characterisation of thyroid cancer types 
has begun to infl uence the diagnosis and treatment of 
thyroid cancer. We expect continued improvements in 
these tests to lead to a reduction in unnecessary treatments 
for indolent thyroid cancers and to improvements in 
outcomes in patients with clinically aggressive cancers.
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